Scholarlink

Exon-skipping therapy is an emerging approach that uses synthetic DNA-like molecules called antisense oligonucleotides (ASOs) to splice out frame-disrupting regions of mRNA, restoring the reading frame, and produce truncated yet functional proteins. Phosphorodiamidate morpholino oligomers (PMOs) are one of the safest among therapeutic ASOs for patients and have recently been approved under the accelerated approval program by the US Food and Drug Administration (FDA) as the first ASO-based drug for Duchenne muscular dystrophy (DMD). Multi-exon-skipping utilizing ASOs can theoretically treat 80–90% of patients with DMD. Here, we describe the systemic delivery of a cocktail of ASOs to skip exon 51 and exons 45 to 55 in the mdx52 mouse, an exon 52 deletion model of DMD produced by gene targeting, and the evaluation of their efficacies in vivo.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In Vivo Evaluation of Single- and Multi-Exon-Skipping in mdx52 Mice

  • 实验方案

  • 发表日期：

    2025年

查看全文
  • Chaitra Sathyaprakash,
  • Eri Takeuchi,
  • Hotake Takizawa,
  • Yuki Ashida,
  • Tsukasa Tominari,
  • Yusuke Echigoya,
  • Toshifumi Yokota,
  • Yoshitsugu Aoki

摘要

Exon-skipping therapy is an emerging approach that uses synthetic DNA-like molecules called antisense oligonucleotides (ASOs) to splice out frame-disrupting regions of mRNA, restoring the reading frame, and produce truncated yet functional proteins. Phosphorodiamidate morpholino oligomers (PMOs) are one of the safest among therapeutic ASOs for patients and have recently been approved under the accelerated approval program by the US Food and Drug Administration (FDA) as the first ASO-based drug for Duchenne muscular dystrophy (DMD). Multi-exon-skipping utilizing ASOs can theoretically treat 80–90% of patients with DMD. Here, we describe the systemic delivery of a cocktail of ASOs to skip exon 51 and exons 45 to 55 in the mdx52 mouse, an exon 52 deletion model of DMD produced by gene targeting, and the evaluation of their efficacies in vivo.